Ian Jones
Ian Jones has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Bernard David Naughton
The School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin, Ireland
1 shared publication - Caroline McCormack
InnoGlobal Technology, Ravenscourt Campus, D18 K599 Dublin, Ireland
1 shared publication - Chris O’callaghan
InnoGlobal Technology, Ravenscourt Campus, D18 K599 Dublin, Ireland
1 shared publication - David Egan
University of Limerick
1 shared publication - Eleni Niarchou
School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin, Ireland
1 shared publication - Gavin M. Walker
Department of Chemical Sciences, University of Limerick, Limerick, Ireland
1 shared publication
Latest Publications
- Open Access
- 27 November 2025
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 21 (1) , 46
Emerging Digital Innovations in Pharmaceutical Manufacturing Quality: A Systematised Review
Purpose: This study explores emerging digital innovations in pharmaceutical manufacturing, as well as the opportunities and challenges they present for product quality and batch release. A secondary objective was to discuss the regulatory compliance of these digital innovations. Method: A comprehensive systematised literature review was performed using Web of Science, PubMed, and Scopus research databases. Screening of the identified studies was performed using Covidence online software. The Mixed Methods Appraisal Tool (MMAT) was adapted for the risk of bias assessment. Results: 38 studies were included after screening and risk of bias assessment. The thematic analysis identified 5 empirical themes: ‘PAT and RTRT’ ‘AI’, ‘Process Modelling’ ‘IoT’, and ‘Data Management’. The main opportunities identified included prediction of product quality and variability, deviation root cause analysis, real-time process monitoring, and adaptive control to prevent out of specification products. This study didn’t identify any regulatory challenges to these technologies, however challenges included a lack of personnel with the required technical expertise, data security risks, validation challenges, and potential for inaccuracy. Conclusions: Emerging digital technologies are being used to support pharmaceutical quality. A review of current guidance did not uncover any regulatory obstacles to theimplementation of the identified technologies, once part of the registered manufacturing process. More opportunities than challenges were identified in the literature. Based on this study, we propose a responsible strategy for future digital innovation implementation and conclude that there is value in (1) Adopting digital innovations in pharmaceutical manufacturing and (2) Supporting digital education for QPs and other quality professionals in pharmaceutical manufacturing.
- 27 November 2025
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 21 (1) , 46
Open AccessEmerging Digital Innovations in Pharmaceutical Manufacturing Quality: A Systematised Review
Purpose: This study explores emerging digital innovations in pharmaceutical manufacturing, as well as the opportunities and challenges they present for product quality and batch release. A secondary objective was to discuss the regulatory compliance of these digital innovations. Method: A comprehensive systematised literature review was performed using Web of Science, PubMed, and Scopus research databases. Screening of the identified studies was performed using Covidence online software. The Mixed Methods Appraisal Tool (MMAT) was adapted for the risk of bias assessment. Results: 38 studies were included after screening and risk of bias assessment. The thematic analysis identified 5 empirical themes: ‘PAT and RTRT’ ‘AI’, ‘Process Modelling’ ‘IoT’, and ‘Data Management’. The main opportunities identified included prediction of product quality and variability, deviation root cause analysis, real-time process monitoring, and adaptive control to prevent out of specification products. This study didn’t identify any regulatory challenges to these technologies, however challenges included a lack of personnel with the required technical expertise, data security risks, validation challenges, and potential for inaccuracy. Conclusions: Emerging digital technologies are being used to support pharmaceutical quality. A review of current guidance did not uncover any regulatory obstacles to theimplementation of the identified technologies, once part of the registered manufacturing process. More opportunities than challenges were identified in the literature. Based on this study, we propose a responsible strategy for future digital innovation implementation and conclude that there is value in (1) Adopting digital innovations in pharmaceutical manufacturing and (2) Supporting digital education for QPs and other quality professionals in pharmaceutical manufacturing.
- Open Access
- 29 May 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (6) , 720
Merging Real-Time NIR and Process Parameter Measurements in a Fluidized Bed Granulation Process to Predict Particle Size
Background/Objectives: Controlling the critical quality attributes (CQAs), such as granule moisture level and particle size distribution, that impact product performance is essential for ensuring product quality in medicine manufacture. Oral solid dosage forms, such as tablets, often require appropriate powder flow for compaction and filling. Spray-dried fluidized bed granulation (FBG) is a key unit operation in the preparation of granulated powders. The determination of particle sizes in FBG using near-infrared spectroscopy (NIR) has been considered in the literature. Herein, for the first time, NIR is combined with process parameters to achieve improved prediction of the particle sizes in FBG. Methods: An inline model for particle size determination using both NIR and FBG process parameters was developed using the partial least square (PLS) method, or ‘merged-PLS model’. The particle size was predicted at the end point of the process, i.e., the last 10% of the particle-size data for each batch run. An additional two analyses included a merged-PLS model with 12 batches: (1) where nine batches were training and three batches were a test set; and (2) where 11 batches were training and one was a test batch. Results: For all considered particle size fractions, Dv10, Dv25, Dv50, Dv75, and Dv90, an improved root-mean-squared error of prediction (RMSEP) is obtained for the merged-PLS model compared to the NIR-only PLS model and compared to the process parameters alone model. Improved RMSEP is also achieved for the additional two analyses. Conclusions: The improved prediction performance of endpoint particle sizes by the merged-PLS model can help to enhance both the process understanding and the overall control of the FBG process.
- 29 May 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (6) , 720
Open AccessMerging Real-Time NIR and Process Parameter Measurements in a Fluidized Bed Granulation Process to Predict Particle Size
Background/Objectives: Controlling the critical quality attributes (CQAs), such as granule moisture level and particle size distribution, that impact product performance is essential for ensuring product quality in medicine manufacture. Oral solid dosage forms, such as tablets, often require appropriate powder flow for compaction and filling. Spray-dried fluidized bed granulation (FBG) is a key unit operation in the preparation of granulated powders. The determination of particle sizes in FBG using near-infrared spectroscopy (NIR) has been considered in the literature. Herein, for the first time, NIR is combined with process parameters to achieve improved prediction of the particle sizes in FBG. Methods: An inline model for particle size determination using both NIR and FBG process parameters was developed using the partial least square (PLS) method, or ‘merged-PLS model’. The particle size was predicted at the end point of the process, i.e., the last 10% of the particle-size data for each batch run. An additional two analyses included a merged-PLS model with 12 batches: (1) where nine batches were training and three batches were a test set; and (2) where 11 batches were training and one was a test batch. Results: For all considered particle size fractions, Dv10, Dv25, Dv50, Dv75, and Dv90, an improved root-mean-squared error of prediction (RMSEP) is obtained for the merged-PLS model compared to the NIR-only PLS model and compared to the process parameters alone model. Improved RMSEP is also achieved for the additional two analyses. Conclusions: The improved prediction performance of endpoint particle sizes by the merged-PLS model can help to enhance both the process understanding and the overall control of the FBG process.